Amy Lin, MD

Title(s)Professor, Medicine
SchoolSchool of Medicine
AddressLocation Required, #001
Phone415-502-0299
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    Oregon Health Sciences UniversityGraduate certificateCurrentBiomedical and Health Informatics
    University of California, San FranciscoFellowship2006Oncology: Genitourinary Medical Oncology
    New York Presbyterian Hospital CornellResidency2002Internal Medicine
    University of Chicago PritzkerM.D.1999School of Medicine
    Harvard UniversityA.B. 1993Biology
    Collapse Awards and Honors
    University of California San Francisco2015Pinnacle "Voice of the Patient" Team Award
    Marin Magazine2015  - 2017[415] Top Doctors
    Cancer and Leukemia Group B (CALGB)2007Young Investigator Award
    American Society of Clinical Oncology2005Young Investigator Award
    American Society of Clinical Oncology2005 Prostate Cancer Symposium Merit Award
    AACR/ASCO2004Clinical Cancer Research Workshop
    University of Chicago1998Calvin Fentress Research Fellowship Award
    Harvard University1992Elizabeth Agassiz Award
    Harvard University1991John Harvard Scholarship for Academic Excellence
    Harvard University1990Harvard College Scholarship

    Collapse Overview 
    Collapse Overview
    Amy M Lin joined the UCSF faculty in 2005 as a genitourinary medical oncologist. From 2005 to 2018, Dr. Lin worked in a multidisciplinary team of medical oncologists, radiation oncologists, and urologic surgical oncologists both at UCSF and the San Francisco Veterans Administration Medical Center providing specialized outpatient patient care to all types of genitourinary malignancies including prostate, kidney, bladder and testicular cancer. In 2018, Dr. Lin joined UCSF’s inpatient hospital-based solid tumor oncology program as a faculty member and chief of clinical operations. She also serves as the Medical Director of Clinical Informatics and Data Analytics for Adult Cancer Services at the Helen Diller Comprehensive Cancer Center. She is currently a Professor of Medicine and Urology.

    Dr. Lin’s focus is on improving clinical care workflows to optimize health care delivery. She is interested in how health care technology can enhance certain aspects of patient care and believes that increasing the quality of health care data collection, integration of multi-source patient health care data, and data interoperability are key to these efforts. Dr. Lin has been an active subject matter expert on electronic health record (EHR) clinical workflows within the Cancer Center.

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Assessing Unique Risk Factors for COVID-19 Complications Among Cancer Patients: A Multi-ethnic Cohort Study. J Immigr Minor Health. 2023 Jun; 25(3):624-633. Borno HT, Kim MO, Tolstykh I, Lin A, Hong JC, Yousefi S, Zhang S, McKay RR, Harismendy O, Razavi P, Cinar P, Rugo H, Koshkin VS, Rabow M, Wang C, Bailey A, Small EJ. PMID: 36344859; PMCID: PMC9640901.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    2. Improving Time to Molecular Testing Results in Patients With Newly Diagnosed, Metastatic Non-Small-Cell Lung Cancer. JCO Oncol Pract. 2022 Nov; 18(11):e1874-e1884. Ossowski S, Neeman E, Borden C, Stram D, Giraldo L, Kotak D, Thomas S, Suga JM, Lin A, Liu R. PMID: 36191286.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    3. COVID-19 Outcomes Among Patients With Cancer: Observations From the University of California Cancer Consortium COVID-19 Project Outcomes Registry. Oncologist. 2022 05 06; 27(5):398-406. Borno HT, Kim MO, Hong JC, Yousefi S, Lin A, Tolstykh I, Zhang S, McKay RR, Harismendy O, Cinar P, Rugo H, Koshkin VS, Rabow M, Wang C, Bailey A, Small EJ. PMID: 35348771; PMCID: PMC9074994.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCells
    4. Mobile Clinical Trial Matching Technology in Medical Oncology Clinic: A Pilot Feasibility Study. JCO Clin Cancer Inform. 2022 05; 6:e2100182. Borno HT, Zhang L, Zhang S, Kaplan C, Palmer NR, Bell A, Bakke B, Lin A, Aggarwal R, Small EJ. PMID: 35584338; PMCID: PMC9173564.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    5. A multidisciplinary team-based approach with lifestyle modification and symptom management to address the impact of androgen deprivation therapy in prostate cancer: A randomized phase II study. Urol Oncol. 2021 10; 39(10):730.e9-730.e15. Pollock Y, Zhang L, Kenfield SA, Van Blarigan EL, Rodvelt T, Rabow M, Macaire G, Weinberg R, Topp K, Friedlander T, Lin A, Fong L, Kim W, Ma B, Hough J, Lee M, Paciorek A, Ryan CJ, Chan JM, Small E, Aggarwal R. PMID: 34304981.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCTClinical Trials
    6. Factors Associated With Participation in the Chronic Disease Self-Management Program: Findings From the SUCCEED Trial. Stroke. 2020 10; 51(10):2910-2917. Lin AM, Vickrey BG, Barry F, Lee ML, Ayala-Rivera M, Cheng E, Montoya AV, Mojarro-Huang E, Gomez P, Castro M, Corrales M, Sivers-Teixeira T, Tran JL, Johnson R, Ediss C, Shaby B, Willis P, Sanossian N, Mehta B, Dutta T, Razmara A, Bryg R, Song S, Towfighi A. PMID: 32912091; PMCID: PMC8269960.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansPHPublic Health
    7. Mapping Subcortical Brain Alterations in 22q11.2 Deletion Syndrome: Effects of Deletion Size and Convergence With Idiopathic Neuropsychiatric Illness. Am J Psychiatry. 2020 07 01; 177(7):589-600. Ching CRK, Gutman BA, Sun D, Villalon Reina J, Ragothaman A, Isaev D, Zavaliangos-Petropulu A, Lin A, Jonas RK, Kushan L, Pacheco-Hansen L, Vajdi A, Forsyth JK, Jalbrzikowski M, Bakker G, van Amelsvoort T, Antshel KM, Fremont W, Kates WR, Campbell LE, McCabe KL, Craig MC, Daly E, Gudbrandsen M, Murphy CM, Murphy DG, Murphy KC, Fiksinski A, Koops S, Vorstman J, Crowley TB, Emanuel BS, Gur RE, McDonald-McGinn DM, Roalf DR, Ruparel K, Schmitt JE, Zackai EH, Durdle CA, Goodrich-Hunsaker NJ, Simon TJ, Bassett AS, Butcher NJ, Chow EWC, Vila-Rodriguez F, Cunningham A, Doherty J, Linden DE, Moss H, Owen MJ, van den Bree M, Crossley NA, Repetto GM, Thompson PM, Bearden CE. PMID: 32046535; PMCID: PMC7419015.
      View in: PubMed   Mentions: 32     Fields:    Translation:Humans
    8. Less Than Ideal: Trends in Cardiovascular Health Among US Stroke Survivors. Stroke. 2019 Jan; 50(1):5-12. Lin AM, Lin MP, Markovic D, Ovbiagele B, Sanossian N, Towfighi A. PMID: 30580724.
      View in: PubMed   Mentions: 5     Fields:    
    9. Itraconazole as a Noncastrating Treatment for Biochemically Recurrent Prostate Cancer: A Phase 2 Study. Clin Genitourin Cancer. 2019 Feb; 17(1):e92-e96. Lee M, Hong H, Kim W, Zhang L, Friedlander TW, Fong L, Lin AM, Small EJ, Wei XX, Rodvelt TJ, Miralda B, Stocksdale B, Ryan CJ, Aggarwal R. PMID: 30327180.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCTClinical Trials
    10. A Phase II Trial of Selinexor, an Oral Selective Inhibitor of Nuclear Export Compound, in Abiraterone- and/or Enzalutamide-Refractory Metastatic Castration-Resistant Prostate Cancer. Oncologist. 2018 06; 23(6):656-e64. Wei XX, Siegel AP, Aggarwal R, Lin AM, Friedlander TW, Fong L, Kim W, Louttit M, Chang E, Zhang L, Ryan CJ. PMID: 29487219; PMCID: PMC6067936.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansCTClinical Trials
    11. High-Dose Abiraterone Acetate in Men With Castration Resistant Prostate Cancer. Clin Genitourin Cancer. 2017 12; 15(6):733-741.e1. Friedlander TW, Graff JN, Zejnullahu K, Anantharaman A, Zhang L, Paz R, Premasekharan G, Russell C, Huang Y, Kim W, Aggarwal RR, Lin AM, Fong L, Alumkal JJ, Beer TM, Sharifi N, Alyamani M, Dittamore R, Small EJ, Paris PL, Ryan CJ. PMID: 28655452.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCTClinical Trials
    12. A Phase I Study of Abiraterone Acetate Combined with BEZ235, a Dual PI3K/mTOR Inhibitor, in Metastatic Castration Resistant Prostate Cancer. Oncologist. 2017 05; 22(5):503-e43. Wei XX, Hsieh AC, Kim W, Friedlander T, Lin AM, Louttit M, Ryan CJ. PMID: 28314838; PMCID: PMC5423513.
      View in: PubMed   Mentions: 30     Fields:    Translation:HumansCellsCTClinical Trials
    13. A multicenter phase I study of cabazitaxel, mitoxantrone, and prednisone for chemotherapy-naïve patients with metastatic castration-resistant prostate cancer: A department of defense prostate cancer clinical trials consortium study. Urol Oncol. 2017 04; 35(4):149.e7-149.e13. Aggarwal R, Bryce A, Ryan CJ, Harzstark A, Derleth C, Kim W, Friedlander T, Lin AM, Rodvelt-Bagchi T, Dhawan M, Zhang L, Lee M, Siebeneck E, Hough J, Small EJ. PMID: 28161323.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCTClinical Trials
    14. Systemic GM-CSF Recruits Effector T Cells into the Tumor Microenvironment in Localized Prostate Cancer. Cancer Immunol Res. 2016 11; 4(11):948-958. Wei XX, Chan S, Kwek S, Lewis J, Dao V, Zhang L, Cooperberg MR, Ryan CJ, Lin AM, Friedlander TW, Rini B, Kane C, Simko JP, Carroll PR, Small EJ, Fong L. PMID: 27688020; PMCID: PMC5115633.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansCells
    15. Preexisting Levels of CD4 T Cells Expressing PD-1 Are Related to Overall Survival in Prostate Cancer Patients Treated with Ipilimumab. Cancer Immunol Res. 2015 Sep; 3(9):1008-16. Kwek SS, Lewis J, Zhang L, Weinberg V, Greaney SK, Harzstark AL, Lin AM, Ryan CJ, Small EJ, Fong L. PMID: 25968455; PMCID: PMC4561203.
      View in: PubMed   Mentions: 37     Fields:    Translation:HumansCellsCTClinical Trials
    16. Intermittent Chemotherapy as a Platform for Testing Novel Agents in Patients With Metastatic Castration-Resistant Prostate Cancer: A Department of Defense Prostate Cancer Clinical Trials Consortium Randomized Phase II Trial of Intermittent Docetaxel With Prednisone With or Without Maintenance GM-CSF. Clin Genitourin Cancer. 2015 Jun; 13(3):e191-8. Aggarwal RR, Beer TM, Weinberg VK, Higano C, Taplin ME, Ryan CJ, Lin AM, Alumkal J, Graff JN, Nordquist LT, Herrera I, Small EJ. PMID: 25557266.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCTClinical Trials
    17. Sequential use of the androgen synthesis inhibitors ketoconazole and abiraterone acetate in castration-resistant prostate cancer and the predictive value of circulating androgens. Clin Cancer Res. 2014 Dec 15; 20(24):6269-76. Kim W, Zhang L, Wilton JH, Fetterly G, Mohler JL, Weinberg V, Morse A, Szmulewitz RZ, Friedlander TW, Fong L, Lin AM, Harzstark AL, Molina A, Small EJ, Ryan CJ. PMID: 25336698; PMCID: PMC4277885.
      View in: PubMed   Mentions: 20     Fields:    Translation:HumansCTClinical Trials
    18. Intestinal tumor suppression in ApcMin/+ mice by prostaglandin D2 receptor PTGDR. Cancer Med. 2014 Aug; 3(4):1041-51. Tippin BL, Kwong AM, Inadomi MJ, Lee OJ, Park JM, Materi AM, Buslon VS, Lin AM, Kudo LC, Karsten SL, French SW, Narumiya S, Urade Y, Salido E, Lin HJ. PMID: 24729479; PMCID: PMC4303173.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansAnimals
    19. Combined alloreactive CTL cellular therapy with prodrug activator gene therapy in a model of breast cancer metastatic to the brain. Clin Cancer Res. 2013 Aug 01; 19(15):4137-48. Hickey MJ, Malone CC, Erickson KL, Lin A, Soto H, Ha ET, Kamijima S, Inagaki A, Takahashi M, Kato Y, Kasahara N, Mueller BM, Kruse CA. PMID: 23780889; PMCID: PMC3939036.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansAnimalsCells
    20. A phase II study of insulin-like growth factor receptor inhibition with nordihydroguaiaretic acid in men with non-metastatic hormone-sensitive prostate cancer. Oncol Rep. 2012 Jan; 27(1):3-9. Friedlander TW, Weinberg VK, Huang Y, Mi JT, Formaker CG, Small EJ, Harzstark AL, Lin AM, Fong L, Ryan CJ. PMID: 21971890.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansCTClinical Trials
    21. Hematopoietic prostaglandin D synthase (HPGDS): a high stability, Val187Ile isoenzyme common among African Americans and its relationship to risk for colorectal cancer. Prostaglandins Other Lipid Mediat. 2012 Jan; 97(1-2):22-8. Tippin BL, Levine AJ, Materi AM, Song WL, Keku TO, Goodman JE, Sansbury LB, Das S, Dai A, Kwong AM, Lin AM, Lin JM, Park JM, Patterson RE, Chlebowski RT, Garavito RM, Inoue T, Cho W, Lawson JA, Kapoor S, Kolonel LN, Le Marchand L, Haile RW, Sandler RS, Lin HJ. PMID: 21821144; PMCID: PMC3226866.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansAnimalsCells
    22. A phase 1 study of everolimus and sorafenib for metastatic clear cell renal cell carcinoma. Cancer. 2011 Sep 15; 117(18):4194-200. Harzstark AL, Small EJ, Weinberg VK, Sun J, Ryan CJ, Lin AM, Fong L, Brocks DR, Rosenberg JE. PMID: 21387258.
      View in: PubMed   Mentions: 27     Fields:    Translation:HumansCTClinical Trials
    23. Tumor fistulization associated with targeted therapy: computed tomographic findings and clinical consequences. J Comput Assist Tomogr. 2011 Jan-Feb; 35(1):86-90. Chow H, Jung A, Talbott J, Lin AM, Daud AI, Coakley FV. PMID: 21245693; PMCID: PMC3675219.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    24. Effect of the somatostatin analog octreotide acetate on circulating insulin-like growth factor-1 and related peptides in patients with non-metastatic castration-resistant prostate cancer: results of a phase II study. Urol Oncol. 2012 Jul-Aug; 30(4):408-14. Friedlander TW, Weinberg VK, Small EJ, Sharib J, Harzstark AL, Lin AM, Fong L, Ryan CJ. PMID: 20884247.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCTClinical Trials
    25. Asymptomatic maternal combined homocystinuria and methylmalonic aciduria (cblC) detected through low carnitine levels on newborn screening. J Pediatr. 2009 Dec; 155(6):924-7. Lin HJ, Neidich JA, Salazar D, Thomas-Johnson E, Ferreira BF, Kwong AM, Lin AM, Jonas AJ, Levine S, Lorey F, Rosenblatt DS. PMID: 19914430.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansPHPublic Health
    26. Potentiating endogenous antitumor immunity to prostate cancer through combination immunotherapy with CTLA4 blockade and GM-CSF. Cancer Res. 2009 Jan 15; 69(2):609-15. Fong L, Kwek SS, O'Brien S, Kavanagh B, McNeel DG, Weinberg V, Lin AM, Rosenberg J, Ryan CJ, Rini BI, Small EJ. PMID: 19147575.
      View in: PubMed   Mentions: 125     Fields:    Translation:HumansCellsCTClinical Trials
    27. Prostate cancer update: 2007. Curr Opin Oncol. 2008 May; 20(3):294-9. Lin AM, Small EJ. PMID: 18391629.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansPHPublic Health
    28. A pilot dose-escalation study of the effects of nordihydroguareacetic acid on hormone and prostate specific antigen levels in patients with relapsed prostate cancer. BJU Int. 2008 Feb; 101(4):436-9. Ryan CJ, Harzstark AH, Rosenberg J, Lin A, Claros C, Goldfine ID, Kerner JF, Small EJ, Youngren JF. PMID: 18234062.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    29. Phase II study of ketoconazole plus granulocyte-macrophage colony-stimulating factor for prostate cancer: effect of extent of disease on outcome. J Urol. 2007 Dec; 178(6):2372-6; discussion 2377. Ryan CJ, Weinberg V, Rosenberg J, Fong L, Lin A, Kim J, Small EJ. PMID: 17936834.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCTClinical Trials
    30. Management of hormone refractory prostate cancer. Curr Opin Support Palliat Care. 2007 Oct; 1(3):187-91. Lin AM, Small EJ. PMID: 18685361.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    31. A phase I trial of docetaxel/estramustine/imatinib in patients with hormone-refractory prostate cancer. Clin Genitourin Cancer. 2007 Jun; 5(5):323-8. Lin AM, Rini BI, Derynck MK, Weinberg V, Park M, Ryan CJ, Rosenberg JE, Bubley G, Small EJ. PMID: 17645829.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansCTClinical Trials
    32. Prostate cancer update: 2006. Curr Opin Oncol. 2007 May; 19(3):229-33. Lin AM, Small EJ. PMID: 17414641.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    33. The role of trastuzumab in early stage breast cancer: current data and treatment recommendations. Curr Treat Options Oncol. 2007 Feb; 8(1):47-60. Lin A, Rugo HS. PMID: 17660958.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    34. Intermittent chemotherapy for metastatic hormone refractory prostate cancer. Crit Rev Oncol Hematol. 2007 Mar; 61(3):243-54. Lin AM, Ryan CJ, Small EJ. PMID: 17161610.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    35. A phase II trial of imatinib mesylate in patients with biochemical relapse of prostate cancer after definitive local therapy. BJU Int. 2006 Oct; 98(4):763-9. Lin AM, Rini BI, Weinberg V, Fong K, Ryan CJ, Rosenberg JE, Fong L, Small EJ. PMID: 16796694.
      View in: PubMed   Mentions: 22     Fields:    Translation:HumansCTClinical Trials
    36. Immunotherapy for prostate cancer using prostatic acid phosphatase loaded antigen presenting cells. Urol Oncol. 2006 Sep-Oct; 24(5):434-41. Lin AM, Hershberg RM, Small EJ. PMID: 16962496.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCells
    37. Clinical trials in patients with biochemically relapsed prostate cancer. BJU Int. 2006 May; 97(5):905-10. Lin AM, Rini BI, Small EJ. PMID: 16643469.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    38. Angiogenesis inhibition plus chemotherapy for metastatic hormone refractory prostate cancer: history and rationale. Urol Oncol. 2006 May-Jun; 24(3):250-3. Ryan CJ, Lin AM, Small EJ. PMID: 16678059.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    Amy's Networks
    Concepts (228)
    Derived automatically from this person's publications.
    _
    Co-Authors (42)
    People in Profiles who have published with this person.
    _
    Similar People (60)
    People who share similar concepts with this person.
    _
    Same Department
    Search Department
    _